What is Ani Pharmaceuticals Inc worth?
With the base-case assumptions below, a discounted cash flow model on Ani Pharmaceuticals Inc's reported free cash flow gives $272.55 per share. The share price was $67.79 on November 9, 2026, 75% below that value.
Inputs from the filings
Three sets of assumptions
| Case | Growth yrs 1-5 | Discount rate | Value per share | Value vs price |
|---|---|---|---|---|
| Bear | 10.0% | 10.0% | $167.88 | +148% |
| Base | 15.0% | 9.0% | $272.55 | +302% |
| Bull | 20.0% | 8.0% | $467.46 | +590% |
Sensitivity: base case value per share
| 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | |
|---|---|---|---|---|---|
| 7.0% | $351.80 | $376.51 | $406.71 | $444.46 | $493.00 |
| 8.0% | $292.27 | $308.29 | $327.23 | $349.96 | $377.73 |
| 9.0% | $248.95 | $259.91 | $272.55 | $287.30 | $304.73 |
| 10.0% | $216.11 | $223.90 | $232.73 | $242.82 | $254.47 |
| 11.0% | $190.41 | $196.12 | $202.50 | $209.69 | $217.83 |
Where the presets come from
Base: years 1 to 5 grow at Ani Pharmaceuticals Inc's revenue growth rate over the last 5 fiscal years (33.5% a year), held between -5% and 15%. Years 6 to 10 grow halfway between that and the long-run rate of 2.5%. Future cash is discounted at 9% a year.
Bear: 5 points less growth, 2% long-run growth, 10% discount rate. Bull: 5 points more growth (at most 25%), 3% long-run growth, 8% discount rate.
Value per share = (present value of 10 years of free cash flow + present value of everything after + cash - debt) / diluted shares.
This is a model run on assumptions, not a recommendation or a price target. Small changes in the discount rate or growth move the result a lot, as the table above shows. Change them yourself in the calculator.
Adjust the assumptions
Move the sliders for growth, long-run growth and discount rate, or switch to average free cash flow, and see the value per share change.
Adjust the assumptions